Availability of modern diagnostics and treatment of Alzheimer’s disease. Disease-modifying therapy

doi:https://doi.org/10.17116/medtech20254701111

Journal: Medical Technologies. Assessment and Choice. 2025;47(1): 11‑17

DOI: 10.17116/medtech20254701111

Read: 619 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Availability of modern diagnostics and treatment of Alzheimer’s disease. Disease-modifying therapy. Medical Technologies. Assessment and Choice. 2025;47(1):11‑17. (In Russ.)
https://doi.org/10.17116/medtech20254701111

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)

Использование инфографики авторами научных работ

References:

World Alzheimer Report, 2024. https://www.alzint.org/u/World-Alzheimer-Report-2024.pdf
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022 Feb;7(2):e105-e125. https://doi.org/10.1016/S2468-2667(21)00249-8
World Health Organization. The top 10 causes of death, 2020. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
2020 Alzheimer Europe Report: Dementia as a European Priority — A Policy Overview. https://www.alzheimer-europe.org/resources/publications/2020-alzheimer-europe-report-dementia-european-priority-policy-overview
World Alzheimer Report 2015. The global impact of dementia: An analysis of prevalence, incidence, cost and trends. https://www.alzint.org/resource/world-alzheimer-report-2015
Belousov YuB, Zyryanov SK, Belousov DYu, Beketov AS. Kliniko-ekonomicheskie aspekty terapii bolezni Alcgeymera v Rossii. Kachestvennaya Klinicheskaya Praktika=Good Clinical Practice. 2009;(1):3-28. (In Russ.).
Sluchevskaya SF. Kliniko-epidemiologicheskaya kharakteristika i organizaciya mediko-socialnoy pomoshhi psikhicheski bolnym pozhilogo vozrasta v Sankt-Peterburge: avtoref. dis. kand. med. nauk. SPb, 2008; 201 s. (In Russ.).
Vasenina EE, Levin OS, Sonin AG. Modern trends in epidemiology of dementia and management of patients with cognitive impairment. SS. Korsakov Journal of Neurology and Psychiatry. 2017;117(6-2):87-95. (In Russ.). https://doi.org/10.17116/jnevro20171176287-95
van Dyck CH, Chad J. Swanson, Aisen P, Bateman RJ, Chen Ch, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 2023 Jan 5;388(1):9-21. https://doi.org/10.1056/NEJMoa2212948
Cohen S, van Dyck CH, Gee M, Doherty T, Kanekiyo M, Dhadda S, et al. Journal of prevention of Alzheimer’s disease. 2023; 4(10):771-777. https://doi.org/10.14283/jpad.2023.123
Honig L, Sabbagh MN, van Dyck ChH, Sperling RA, Hersch S, Matta A, et al. Updated results from phase 3 lecanemab study in early Alzheimer’s Disease. Alzheimer’s Research & Therapy. 2024;16:105. https://doi.org/10.1186/s13195-024-01441-8
Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: Appropriate Use Recommendations. Journal of prevention of Alzheimer’s disease. 2023;10(3):362-377. https://doi.org/10.14283/jpad.2023.30
Cohen S, editor Clarity AD results in context. 2022 CLARITY AD CTAD Presentations. Clinical Trials in Alzheimer’s Disease (CTAD annual meeting). San Francisco, California, November 29th, 2022.2022.
Instrukciya po medicinskomu primeneniyu preparata LEQEMBI® (lecanemab-irmb), SShA, 2023 g. (In Russ.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf
Kognitivnye rasstroystva u lits pozhilogo i starcheskogo vozrasta. Klinicheskie rekomendatsii/Cognitive impairment in elderly. Clinical guidelines https://cr.minzdrav.gov.ru/preview-cr/617_5